+A -A

Tabela:
Comparative View:

2020 Create chart
Net sales revenues 5,879,616
Change in Fair Value of Biological Assets 117,270
Cost of Goods Sold -3,586,746
Depreciation / Amortization / exhaustion -453,953
Exhaustion of biological assets -104,367
Gross Profit 1,851,820
Selling Expenses -781,150
General and Administrative Expenses -237,878
Management Compensation -17,987
Other Operating Compensation -76,298
Equity income from subsidiaries -66,624
Operating Profit before Financial Income and Equity 671,883
Financial Income 132,149
Financial Expenses -269,287
Income Before Income Tax and Social Contribution 534,745
Income and social contribution taxes - current -104,525
Income Tax and Social Contribution - Deferred 23,763
Effect profit from discontinued operation 0
Net Income 453,983
Recurring Net Income 528,180
Recurring EBITDA 1,288,306
EBITDA Margin 21.9 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza